Circulating Carbonic Anhydrase IX and Antiangiogenic Therapy in Breast Cancer

Disease Markers

Volumn 2016, Issue , 2016, Pages

  Brown Glaberman, Ursa ^a   Marron, Marilyn ^b   Chalasani, Pavani ^b   Livingston, Robert ^b   Iannone, Maria ^b   Specht, Jennifer ^c   Stopeck, Alison T ^d  

^a UNIVERSITY OF NEW MEXICO   (United States)

^b UNIVERSITY OF ARIZONA   (United States)

^c UNIVERSITY OF WASHINGTON   (United States)

^d Stony Brook School of Dental Medicine   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOGENESIS INHIBITOR; BIOLOGICAL MARKER; CARBONATE DEHYDRATASE IX; CYCLOPHOSPHAMIDE; DOXORUBICIN; ETOPOSIDE; IMMUNOMODULATING AGENT; IRINOTECAN; PACLITAXEL; SUNITINIB; ANTINEOPLASTIC AGENT; CA9 PROTEIN, HUMAN; CARBONATE DEHYDRATASE; INDOLE DERIVATIVE; PYRROLE DERIVATIVE; TUMOR ANTIGEN;

ANTIANGIOGENIC THERAPY; ARTICLE; BREAST CANCER; BREAST METASTASIS; CANCER ADJUVANT THERAPY; CANCER PATIENT; CANCER PROGNOSIS; CELL HYPOXIA; CELL PH; CONTROLLED STUDY; ENZYME BLOOD LEVEL; ENZYME LINKED IMMUNOSORBENT ASSAY; ENZYME STABILITY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; PROTEIN EXPRESSION; SYSTEMIC THERAPY; TREATMENT RESPONSE; ADULT; AGED; BLOOD; BREAST NEOPLASMS; COMPARATIVE STUDY; ENZYMOLOGY; METASTASIS; MIDDLE AGED; NEOADJUVANT THERAPY;

ADULT; AGED; ANGIOGENESIS INHIBITORS; ANTIGENS, NEOPLASM; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CARBONIC ANHYDRASE IX; CARBONIC ANHYDRASES; CYCLOPHOSPHAMIDE; DOXORUBICIN; FEMALE; HUMANS; INDOLES; MIDDLE AGED; NEOADJUVANT THERAPY; NEOPLASM METASTASIS; PACLITAXEL; PYRROLES;

EID: 84957989615     PISSN: 02780240     EISSN: 18758630     Source Type: Journal    
DOI: 10.1155/2016/9810383     Document Type: Article

References (34)

1. S. Kaluz, M. Kaluzová, S.-Y. Liao, M. Lerman, and E. J. Stanbridge, "Transcriptional control of the tumor- and hypoxia-marker carbonic anhydrase 9: a one transcription factor (HIF-1) show?" Biochimica et Biophysica Acta (BBA) - Reviews on Cancer, vol. 1795, no. 2, pp. 162-172, 2009.
2. C. P. S. Potter and A. L. Harris, "Diagnostic, prognostic and therapeutic implications of carbonic anhydrases in cancer," British Journal of Cancer, vol. 89, no. 1, pp. 2-7, 2003.
3. D. Hanahan and R. A. Weinberg, "Hallmarks of cancer: the next generation," Cell, vol. 144, no. 5, pp. 646-674, 2011.
4. E. Oosterwijk, D. J. Ruiter, P. J. Hoedemaeker et al.,"Monoclonal antibody G 250 recognizes a determinant present in renal-cell carcinoma and absent from normal kidney," International Journal of Cancer, vol. 38, no. 4, pp. 489-494, 1986.
5. T. A. Bismar, F. J. Bianco, H. Zhang et al., "Quantification of G250 mRNA expression in renal epithelial neoplasms by real-time reverse transcription-PCR of dissected tissue from paraffin sections," Pathology, vol. 35, no. 6, pp. 513-517, 2003.
6. G250/MN by HIF-1α in clear cell renal cell carcinoma," Oncogene, vol. 23, no. 33, pp. 5624-5631, 2004.
7. A. B. Stillebroer, P. F. A. Mulders, O. C. Boerman, W. J. G. Oyen, and E. Oosterwijk, "Carbonic anhydrase IX in renal cell carcinoma: implications for prognosis, diagnosis, and therapy," European Urology, vol. 58, no. 1, pp. 75-83, 2010.
8. G. D. Stewart, F. C. O'Mahony, A. Laird et al., "Carbonic anhydrase 9 expression increases with vascular endothelial growth factor-targeted therapy and is predictive of outcome in metastatic clear cell renal cancer," European Urology, vol. 66, no. 5, pp. 956-963, 2014.
9. J. Saarnio, S. Parkkila, A.-K. Parkkila et al., "Immunohistochemistry of carbonic anhydrase isozyme IX (MN/CA IX) in human gut reveals polarized expression in the epithelial cells with the highest proliferative capacity," Journal of Histochemistry and Cytochemistry, vol. 46, no. 4, pp. 497-504, 1998.
10. S. K. Chia, C. C. Wykoff, P. H. Watson et al., "Prognostic significance of a novel hypoxia-regulated marker, carbonic anhydrase IX, in invasive breast carcinoma," Journal of Clinical Oncology, vol. 19, no. 16, pp. 3660-3668, 2001.
11. S. Y. Liao, C. Brewer, J. Závada et al., "Identification of the MN antigen as a diagnostic biomarker of cervical intraepithelial squamous and glandular neoplasia and cervical carcinomas," American Journal of Pathology, vol. 145, no. 3, pp. 598-609, 1994.
12. A. Giatromanolaki, M. I. Koukourakis, E. Sivridis et al., "Expression of hypoxia-inducible carbonic anhydrase-9 relates to angiogenic pathways and independently to poor outcome in non-small cell lung cancer," Cancer Research, vol. 61, no. 21, pp. 7992-7998, 2001.
13. N. J. P. Beasley, C. C. Wykoff, P. H. Watson et al., "Carbonic anhydrase IX, an endogenous hypoxia marker, expression in head and neck squamous cell carcinoma and its relationship to hypoxia, necrosis, and microvessel density," Cancer Research, vol. 61, no. 13, pp. 5262-5267, 2001.
14. J. Závada, Z. Závadová, M. Zat'ovičová, L. Hyršl, and I. Kawaciuk, "Soluble form of carbonic anhydrase IX (CA IX) in the serum and urine of renal carcinoma patients," British Journal of Cancer, vol. 89, no. 6, pp. 1067-1071, 2003.
15. J. M. Specht, B. Kurland, H. M. Linden et al., "A phase II study evaluating the safety and efficacy of sunitinib with weekly paclitaxel followed by doxorubicin and daily oral cyclophosphamide plus G-CSF as neoadjuvant chemotherapy (NC) for locally advanced (LABC) or inflammatory breast cancer (IBC)," Journal of Clinical Oncology, vol. 31, abstract 1090, 2013, ASCO Annual Meeting.
16. U. Brown-Glaberman, J. Specht, M. Iannone et al., "Circulating biomarkers in patients receiving neoadjuvant chemotherapy combined with sunitinib for locally advanced breast cancer," Journal of Clinical Oncology, vol. 31, supplement, abstract 1089, 2013, Proceedings of the ASCO Annual Meeting.
17. T. C. Wind, M. P. Messenger, D. Thompson, P. J. Selby, and R. E. Banks, "Measuring carbonic anhydrase IX as a hypoxia biomarker: differences in concentrations in serum and plasma using a commercial enzyme-linked immunosorbent assay due to influences of metal ions," Annals of Clinical Biochemistry, vol. 48, no. 2, pp. 112-120, 2011.
18. Y. Lou, P. C. McDonald, A. Oloumi et al., "Targeting tumor hypoxia: suppression of breast tumor growth and metastasis by novel carbonic anhydrase IX inhibitors," Cancer Research, vol. 71, no. 9, pp. 3364-3376, 2011.
19. C.-L. Chen, J.-S. Chu, W.-C. Su, S.-C. Huang, and W.-Y. Lee, "Hypoxia and metabolic phenotypes during breast carcinogenesis: expression of HIF-1alpha, GLUT1, and CAIX," Virchows Archiv, vol. 457, no. 1, pp. 53-61, 2010.
20. D. Generali, S. B. Fox, A. Berruti et al., "Role of carbonic anhydrase IX expression in prediction of the efficacy and outcome of primary epirubicin/tamoxifen therapy for breast cancer," Endocrine-Related Cancer, vol. 13, no. 3, pp. 921-930, 2006.
21. S. A. Hussain, R. Ganesan, G. Reynolds et al., "Hypoxia-regulated carbonic anhydrase IX expression is associated with poor survival in patients with invasive breast cancer," British Journal of Cancer, vol. 96, no. 1, pp. 104-109, 2007.
22. E. Y. Tan, M. Yan, L. Campo et al., "The key hypoxia regulated gene CAIX is upregulated in basal-like breast tumours and is associated with resistance to chemotherapy," British Journal of Cancer, vol. 100, no. 2, pp. 405-411, 2009.
23. N. Aomatsu, M. Yashiro, S. Kashiwagi et al., "Carbonic anhydrase 9 is associated with chemosensitivity and prognosis in breast cancer patients treated with taxane and anthracycline," BMC Cancer, vol. 14, no. 1, article 400, 2014.
24. V. Müller, S. Riethdorf, B. Rack et al., "Prospective evaluation of serum tissue inhibitor of metalloproteinase 1 and carbonic anhydrase IX in correlation to circulating tumor cells in patients with metastatic breast cancer," Breast Cancer Research, vol. 13, no. 4, article R71, 2011.
25. R. S. Bindra, S. L. Gibson, A. Meng et al., "Hypoxia-induced down-regulation of BRCA1 expression by E2Fs," Cancer Research, vol. 65, no. 24, pp. 11597-11604, 2005.
26. V. M. Neumeister, C. A. Sullivan, R. Lindner et al., "Hypoxia-induced protein CAIX is associated with somatic loss of BRCA1 protein and pathway activity in triple negative breast cancer," Breast Cancer Research and Treatment, vol. 136, no. 1, pp. 67-75, 2012.
27. P. van der Groep, P. J. van Diest, Y. H. C. M. Smolders et al., "HIF-1α overexpression in ductal carcinoma in Situ of the breast in BRCA1 and BRCA2 mutation carriers," PLoS ONE, vol. 8, no. 2, Article ID e56055, 2013.
28. F. E. Lock, P. C. McDonald, Y. Lou et al., "Targeting carbonic anhydrase IX depletes breast cancer stem cells within the hypoxic niche," Oncogene, vol. 32, no. 44, pp. 5210-5219, 2013.
29. D. Schütze, K. Milde-Langosch, I. Witzel et al., "Relevance of cellular and serum carbonic anhydrase IX in primary breast cancer," Journal of Cancer Research and Clinical Oncology, vol. 139, no. 5, pp. 747-754, 2013.
30. X. Shan, D. Wang, J. Chen et al., "Necrosis degree displayed in computed tomography images correlated with hypoxia and angiogenesis in breast cancer," Journal of Computer Assisted Tomography, vol. 37, no. 1, pp. 22-28, 2013.
31. A. McIntyre, S. Patiar, S. Wigfield et al., "Carbonic anhydrase IX promotes tumor growth and necrosis in vivo and inhibition enhances anti-VEGF therapy," Clinical Cancer Research, vol. 18, no. 11, pp. 3100-3111, 2012.
32. C. Ward, S. P. Langdon, P. Mullen et al., "New strategies for targeting the hypoxic tumour microenvironment in breast cancer," Cancer Treatment Reviews, vol. 39, no. 2, pp. 171-179, 2013.
33. P. C. McDonald, J.-Y. Winum, C. T. Supuran, and S. Dedhar, "Recent developments in targeting carbonic anhydrase IX for cancer therapeutics," Oncotarget, vol. 3, no. 1, pp. 84-97, 2012.
34. P. C. McDonald, J. Sanghera, M. Singh et al., "Therapeutic targeting of cancer cells in the hypoxic microenvironment using an orally bioavailable small molecule inhibitor of carbonic anhydrase IX," Cancer Research, vol. 74, abstract 841, 2014, Proceedings of the AACR Annual Meeting.